(Q37680946)

21 August 2017

1 reference

title

A clinical review of statins and cancer: helpful or harmful? (English)

1 reference

21 August 2017

Michael J Gonyeau

1

1 reference

21 August 2017

Dayton W Yuen

series ordinal

2

1 reference

21 August 2017

language of work or name

English

0 references

publication date

1 February 2010

1 reference

21 August 2017

1 reference

21 August 2017

volume

30

1 reference

21 August 2017

issue

2

1 reference

21 August 2017

page(s)

177-194

1 reference

Cancer risk among statin users: a population-based cohort study

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.2.177

Simvastatin strongly reduces levels of Alzheimer's disease beta -amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.2.177

Anti-inflammatory effects of simvastatin in subjects with hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.2.177

Statin therapy is associated with improved survival in ischemic and non-ischemic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.2.177

Low serum total cholesterol is associated with marked increase in mortality in advanced heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.2.177

Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.2.177

Cholesterol modulates cellular TGF-beta responsiveness by altering TGF-beta binding to TGF-beta receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.2.177

Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.2.177

Serum cholesterol and cancer risk: an epidemiologic perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.2.177

Lovastatin induces mitotic abnormalities in various cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.2.177

The role of statins in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.2.177

Blocking oncogenic Ras signaling for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.2.177

p21-dependent inhibition of colon cancer cell growth by mevastatin is independent of inhibition of G1 cyclin-dependent kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.2.177

Anti-angiogenic and anti-inflammatory effects of statins: relevance to anti-cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.2.177

Statins differentially regulate vascular endothelial growth factor synthesis in endothelial and vascular smooth muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.2.177

The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.2.177

Hsp90 and caveolin are key targets for the proangiogenic nitric oxide-mediated effects of statins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.2.177

Statins have biphasic effects on angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.2.177

Statins prevent oxidized low-density lipoprotein- and lysophosphatidylcholine-induced proliferation of human endothelial cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.2.177

Suppression of invasion and MMP-9 expression in NIH 3T3 and v-H-Ras 3T3 fibroblasts by lovastatin through inhibition of ras isoprenylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.2.177

21 January 2018

The Hallmarks of Cancer

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.2.177

Statins activate the mitochondrial pathway of apoptosis in human lymphoblasts and myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.2.177

Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.2.177

Long-term effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis: The Simvastatin/Enalapril Coronary Atherosclerosis Trial (SCAT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.2.177

Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.2.177

Intensive lipid lowering with atorvastatin in patients with stable coronary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.2.177

High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.2.177

Effects of intense low-density lipoprotein cholesterol reduction in patients with stroke or transient ischemic attack: the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.2.177

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.2.177

Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.2.177

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.2.177

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.2.177

Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.2.177

Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.2.177

Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.2.177

Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S).

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.2.177

Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.2.177

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.2.177

21 January 2018

Statins and cancer risk

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.2.177

Statin use and the risk of 10 cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.2.177

Screening statins for possible carcinogenic risk: up to 9 years of follow-up of 361,859 recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.2.177

Statin use and cancer risk in the General Practice Research Database

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.2.177

The association between statins and cancer incidence in a veterans population

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.2.177

Statins reduce the risk of lung cancer in humans: a large case-control study of US veterans

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.2.177

The effect of statins on serum prostate specific antigen levels in a cohort of airline pilots: a preliminary report

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.2.177

Statins and prostate cancer risk: a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.2.177

Statin drugs and risk of advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.2.177

Statin use and breast cancer: prospective results from the Women's Health Initiative.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.2.177

Serum lipids, lipid-lowering drugs, and the risk of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.2.177

Statins and the risk of colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.2.177

Statins and the risk of colorectal carcinoma: a nested case-control study in veterans with diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.2.177

Statins are associated with a reduced risk of hepatocellular carcinoma in a large cohort of patients with diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.2.177

Statins and cancer risk: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.2.177

21 January 2018

Identifiers

DOI

10.1592/PHCO.30.2.177

1 reference

21 August 2017

1 reference